



14 July 2003

Securities and Exchange Commission  
Judiciary Plaza,  
450 Fifth Street,  
Washington DC 20549



SUPPL

**Re: Bionomics Limited - File number 82-34682**

Please see attached provided pursuant to Section 12g3-2(b) file number 82-34682.


Yours sincerely

*Jill Mashado*  
Jill Mashado  
Company Secretary

PROCESSED  
JUL 30 2003  
THOMSON  
FINANCIAL



*llw 7/24*



**ASX ANNOUNCEMENT  
14 JULY 2003**

**BIONOMICS ENTERS INTO FINANCING ARRANGEMENT WITH AN  
AFFILIATE OF THE BANK OF NEW YORK**

**STANDBY EQUITY FACILITY SIGNED**

Bionomics Limited (ASX:BNO; OTC:BMICY) is pleased to announce that it has entered into a standby equity facility with an affiliate of The Bank of New York, providing for the purchase and on-sale on the ASX of up to 6 million of Bionomics' ordinary shares over the next three years.

At any time over the three year period while Bionomics' shares are trading above a designated floor price (which may be altered from time to time but is presently set at \$0.50), Bionomics will be entitled to issue parcels of shares to The Bank of New York affiliate, subject to satisfying certain conditions precedent which are typical in arrangements of this type. The issue price of the shares is determined by reference to the market price prevailing at the time of issue, with a 3.5% discount to the market applying whilst Bionomics' market capitalization is below \$150 million and a 2% discount to the market applying in the event the Bionomics' market capitalization exceeds \$150 million. Under the terms of the facility, The Bank of New York affiliate is to be issued with an option to acquire a further 60,000 Bionomics' shares.

"This financing arrangement is intended to provide Bionomics with additional capital to actively build our drug discovery and technology platforms ionX® and Angene™ and our programs in epilepsy, breast cancer and angiogenesis" said Dr Deborah Rathjen, Chief Executive Officer and Managing Director of Bionomics.

**About Bionomics Limited**

Bionomics Limited is an ASX listed biotechnology company based in Adelaide, Australia. The Company has an American Depository Receipts (ADRs) program sponsored by The Bank of New York. Bionomics combines its strong genomics-based research focus on the discovery of genes associated with serious medical conditions with validation and development efforts leading to new drugs, gene therapies and diagnostic applications. Bionomics focuses its research and development activities in breast cancer, epilepsy and angiogenesis (a critical process involved in serious diseases such as cancer, chronic inflammatory

diseases and eye diseases). These diseases are in need of improved medical treatments and represent large markets for Bionomics-developed products. Importantly, Bionomics has exclusive access to clinical material and clinical insights, which in combination with its platform of core technologies, diverse set of skills and expertise and strategic academic and commercial collaborations, positions Bionomics as a world leader in the fields of rapid disease gene and drug discovery, therapeutic and diagnostic product development.

Bionomics leverages its gene discoveries in epilepsy with the Bionomics-developed ionX® discovery platform, a novel platform for the discovery and development of new and more effective treatments for epilepsy and other CNS disorders. The global CNS market is the second largest sector of the pharmaceuticals market, valued in 2001 at US\$52 billion and projected to grow to US\$77 billion by 2007.

Angene™, Bionomics' angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and characterise novel angiogenesis targets, utilising Bionomics' novel models of angiogenesis. Bionomics is continuing to develop the Angene™ platform and leveraging its unique attributes for the discovery of novel and more effective drugs for the treatment of cancer and inflammatory diseases.

For more information about Bionomics, visit [www.bionomics.com.au](http://www.bionomics.com.au)

**About The Bank of New York**

The Bank of New York Company (NYSE:BK) is a global leader in securities servicing for issuers, investors and financial intermediaries. The Bank of New York Company plays an integral role in the infrastructure of the capital markets, servicing securities in more than 100 markets worldwide. It provides quality solutions through leading technology for global corporations, financial institutions, asset managers, governments, non-profit organizations and individuals. Its principal subsidiary, The Bank of New York, founded in 1784, is the oldest bank in the United States and has a distinguished history of serving clients around the world through its five primary businesses: Securities Servicing and Global Payment Services, Private Client Services and Asset Management, Corporate Banking, Global Market Services and Retail Banking. Additional information on The Bank of New York Company is available at [www.bankofny.com](http://www.bankofny.com).

---

**FOR FURTHER INFORMATION PLEASE CONTACT:**

**DR DEBORAH RATHJEN  
CEO & MANAGING DIRECTOR  
BIONOMICS LIMITED  
Ph: +61 8 8354 6101**